Marex Group plc Announces Launch of a Public Offering
Marex Group plc (Nasdaq: MRX) has announced a public offering of ordinary shares by its selling shareholders. The offering consists of 8,500,000 ordinary shares, with an additional 30-day option for underwriters to purchase up to 1,275,000 additional shares.
The company itself is not selling any shares and will not receive any proceeds from the offering. Goldman Sachs & Co. , Barclays, and Jefferies are serving as lead book-running managers for the proposed offering.
The offering will be conducted through a prospectus, and a registration statement has been filed with the SEC, pending effectiveness. The sale of securities cannot commence until the registration statement becomes effective.
Marex Group plc (Nasdaq: MRX) ha annunciato un'offerta pubblica di azioni ordinarie da parte dei suoi azionisti venditori. L'offerta comprende 8.500.000 azioni ordinarie, con un'opzione aggiuntiva di 30 giorni per i sottoscrittori di acquistare fino a 1.275.000 azioni supplementari.
La società stessa non sta vendendo azioni e non riceverà alcun ricavo dall'offerta. Goldman Sachs & Co., Barclays e Jefferies sono i principali gestori dell'offerta proposta.
L'offerta sarà effettuata tramite un prospetto e una dichiarazione di registrazione è stata depositata presso la SEC, in attesa di efficacia. La vendita dei titoli non potrà iniziare fino a quando la dichiarazione di registrazione non diventerà efficace.
Marex Group plc (Nasdaq: MRX) ha anunciado una oferta pública de acciones ordinarias por parte de sus accionistas vendedores. La oferta consiste en 8.500.000 acciones ordinarias, con una opción adicional de 30 días para que los suscriptores compren hasta 1.275.000 acciones adicionales.
La compañía no está vendiendo acciones y no recibirá ingresos por la oferta. Goldman Sachs & Co., Barclays y Jefferies actúan como gestores principales del libro para la oferta propuesta.
La oferta se realizará mediante un prospecto, y se ha presentado una declaración de registro ante la SEC, a la espera de su aprobación. La venta de valores no podrá comenzar hasta que la declaración de registro sea efectiva.
Marex Group plc (나스닥: MRX)가 매도 주주들의 보통주 공개 매도를 발표했습니다. 이번 공모는 8,500,000 보통주로 구성되며, 인수인들이 추가로 1,275,000주를 30일간 매수할 수 있는 옵션이 포함되어 있습니다.
회사는 직접 주식을 매도하지 않으며, 공모로부터 어떤 수익도 받지 않습니다. 골드만 삭스 & 컴퍼니, 바클레이즈, 제프리스가 이번 공모의 주간사로 참여하고 있습니다.
공모는 투자설명서를 통해 진행되며, SEC에 등록신고서가 제출되어 효력 발생을 기다리고 있습니다. 등록신고서가 효력을 발휘하기 전까지 증권 판매는 시작될 수 없습니다.
Marex Group plc (Nasdaq : MRX) a annoncé une offre publique d'actions ordinaires par ses actionnaires vendeurs. L'offre comprend 8 500 000 actions ordinaires, avec une option supplémentaire de 30 jours permettant aux souscripteurs d'acheter jusqu'à 1 275 000 actions supplémentaires.
L'entreprise elle-même ne vend pas d'actions et ne percevra aucun produit de l'offre. Goldman Sachs & Co., Barclays et Jefferies agissent en tant que principaux chefs de file pour cette offre proposée.
L'offre sera réalisée via un prospectus, et une déclaration d'enregistrement a été déposée auprès de la SEC, en attente d'effet. La vente des titres ne pourra commencer que lorsque la déclaration d'enregistrement sera effective.
Marex Group plc (Nasdaq: MRX) hat eine öffentliche Platzierung von Stammaktien durch seine verkaufenden Aktionäre angekündigt. Das Angebot umfasst 8.500.000 Stammaktien mit einer zusätzlichen 30-tägigen Option für die Underwriter, bis zu 1.275.000 weitere Aktien zu erwerben.
Das Unternehmen selbst verkauft keine Aktien und erhält keine Erlöse aus dem Angebot. Goldman Sachs & Co., Barclays und Jefferies fungieren als leitende Konsortialführer für das geplante Angebot.
Das Angebot wird durch einen Prospekt durchgeführt, und eine Registrierungserklärung wurde bei der SEC eingereicht und wartet auf Wirksamkeit. Der Verkauf der Wertpapiere darf erst beginnen, wenn die Registrierungserklärung wirksam wird.
- None.
- Potential stock price pressure from 8.5 million shares being sold by existing shareholders
- Additional dilution risk from 1,275,000 share overallotment option
- No capital raised for company operations or growth as proceeds go to selling shareholders
Insights
The announced secondary offering by Marex Group's existing shareholders represents a standard market transaction with several key implications for investors to consider. The selling shareholders are offering 8.5 million ordinary shares with underwriters having an option for an additional 1.275 million shares.
Critical to this analysis is the fact that Marex itself is not selling any shares and will receive no proceeds from the transaction. This means there's no dilution for existing public shareholders, as no new equity is being created. The company's balance sheet, capital structure, and operational capacity remain unchanged.
Secondary offerings typically create temporary technical pressure on share prices due to increased supply, but they also improve liquidity and trading volume - a positive for institutional investors who require certain liquidity thresholds. Without knowing which shareholders are selling or what percentage of outstanding shares this represents, we can't determine if this signals a lack of confidence or simply represents a planned liquidity event for early investors.
The selection of Goldman Sachs, Barclays, and Jefferies as lead underwriters suggests strong institutional support for the offering. The filing status indicates this is still in process, with the registration statement filed but not yet effective with the SEC.
This transaction falls into the category of routine capital markets activity that typically has minimal long-term fundamental impact on company performance or valuation, though investors should monitor for any unusual short-term price volatility following the offering's completion.
NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (Nasdaq: MRX) (“Marex”), the diversified global financial services platform, today announces the launch of a public offering of its ordinary shares (the "Offering”) by certain selling shareholders (the “Selling Shareholders”). The Selling Shareholders are offering a total of 8,500,000 ordinary shares. In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,275,000 ordinary shares.
Marex is not selling any ordinary shares in the Offering and will not receive any proceeds from the sale of shares by the Selling Shareholders.
Goldman Sachs & Co. LLC, Barclays and Jefferies are acting as lead book-running managers and as representatives of the underwriters for the proposed offering.
The proposed Offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed Offering may be obtained from:
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com;
- Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@broadridge.com; or
- Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Enquiries please contact:
Nicola Ratchford / Adam Strachan
Marex
+44 (0) 778 654 8889 / +1 (914) 200 2508 | nratchford@marex.com / astrachan@marex.com
FTI Consulting US / UK
+1 (919) 609-9423 / +44 (0) 7776 111 222 | marex@fticonsulting.com
FAQ
How many shares are being offered in the Marex Group (MRX) public offering?
Will Marex Group (MRX) receive any proceeds from this share offering?
Who are the lead underwriters for the Marex Group (MRX) public offering?
When will the Marex Group (MRX) share offering become effective?
